1. Introduction {#s0005}
===============

Osteosarcoma is an aggressive bone neoplasm arising from primitive transformed cells of mesenchymal origin. It was such a fatal disease that "months to metastasis" rather than actual survival time, was used to measure the outcomes of treatment in studies of early stage. In the 1950s, there was no optional therapy that could significantly increase the survival rate, with a 5-year survival rate of 22% [@bib1]. However, with the aid of effective chemotherapeutic drugs the survival rate of osteosarcoma has been significantly improved since the late 1970s [@bib2], [@bib3]. Recently, the gold standard of osteosarcoma chemotherapy have been based on around 5 drugs; high-dose methotrexate (HDMTX) with leucovorin rescue, doxorubicin (adriamycin), cisplatin, ifosfamide, and etoposide [@bib4]. Combinations of these drugs, mostly in the form of neoadjuvant as well as adjuvant MAP, are the current management for osteosarcoma [@bib5], and various chemotherapy protocols are still under investigation. The experience with radiotherapy is limited, as osteosarcoma is long considered resistant to applicable doses of radiation. However, recent data suggest that the combined approach of irradiation with chemotherapy may be useful in patients who have microscopic residual tumor foci following intralesional resection [@bib6].

With the advent of effective neoadjuvant chemotherapy in the 1970s, limb salvage surgery (LSS) has been taken as a potential treatment for osteosarcoma [@bib7], [@bib8]. Usually, LSS has functional and physiological advantages over traditional amputative procedures when combined with neoadjuvant or adjuvant chemotherapy [@bib9]. It is now generally accepted that LSS is indicative for localized osteosarcoma, while surgical amputation is adopted for high malignancy osteosarcoma. However, there are still some surgeons holding the view that immediate and aggressive removal of the tumor will prevent the progression of fracture-induced disease, and consequently amputation is considered to be a better option for osteosarcoma patients with pathologic fracture [@bib10], [@bib11], [@bib12], [@bib13].

Conflicting findings have been reported on the survival and function recovery between treatments of LSS and amputation in patients with osteosarcoma. Toward this end, a meta-analysis of published clinical trials was performed to compare the clinical efficacy of LSS and amputation treatments in terms of local recurrence, 5-year overall survival rate, and metastatic occurrence. Several studies have attempted similar meta-analysis [@bib14]; however, the included studies were much smaller, and their scopes were restricted to specific therapies compared with this meta-analysis. Through more extensive osteosarcoma literature, this meta-analysis tries to give a comprehensive conclusion on the outcomes in osteosarcoma patients receiving LSS and amputation. Such information will help us determine the most appropriate osteosarcoma-treating method.

2. Material and methods {#s0010}
=======================

2.1. Literature search {#s0015}
----------------------

A comprehensive and complete search of Medline, Embase, Cochrane Database, Web of Sciences, and CNKI was performed from June 2014 to July 2014, using the search terms: "osteosarcoma", "limb salvage" and "amputation". There was no language or other restrictions. All articles with raw descriptive data were included, including original research, clinical trials, case reports, databases, letters, and reviews.

2.2. Included studies {#s0020}
---------------------

Articles were included if they were (1) comparative study between LSS and amputation groups, (2) patients with osteosarcoma in their lower limb, (3) sufficient data was provide in terms of local recurrence, 5-year overall survival rate, or occurrence of metastasis. Exclusion criteria were as follows: (1) studies only reported data related to LSS or amputation groups without a comparison, (2) general case series with less than 20 total patients, (3) letters, case reports, editorials or reviews.

2.3. Data extraction {#s0025}
--------------------

Outcome data were collected from the articles by two authors of our study. The authors used a structured sheet, and then gathered all the data into a database. Study characteristics included year of publication, number of patient with LSS and amputation, study period, gender, Enneking stage, response to chemotherapy, follow-up, etc. Any disagreement was resolved by continuing discussions until a consensus was reached.

2.4. Study quality {#s0030}
------------------

With the Newcastle--Ottawa scale (NOS) quality assessment as recommended by the Cochrane Observational Studies Method Working Group, the quality of included articles was evaluated by two independent reviewers. This scale has a maximum nine points concerning quality of selection, comparability, exposure, and outcome of study participants. Because of the variable quality of the observational studies, we took the criteria of 5 or more NOS scores as studies with good quality.

2.5. Statistical analysis {#s0035}
-------------------------

The outcome of measurement used in our study was local recurrence, 5-year overall survival rate, and occurrence of metastasis, which were all dichotomous data. We used the software of the Cochrane Collaboration (Review Manager 5.2) to calculate OR and 95% CI for all outcomes. Statistical heterogeneity among the included studies was assessed by the Chi squared and *I*^2^ tests. Statistically significant heterogeneity was defined as an *I*^2^ value\>0.5. A random effects model was selected for heterogeneous data; otherwise, a fixed effect model was selected.

Funnel plots were used to test the possibility of publication bias, which exhibited the intervention effect from the individual study against the respective standard error. A symmetrical plot represents no bias, and any asymmetry of the plot suggests the existence of publication bias.

3. Results {#s0040}
==========

3.1. Literature information {#s0045}
---------------------------

In the preliminary literature search, 137 potentially relevant articles were identified. However, according to the inclusion criteria, only 17 articles [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31] were selected ([Fig. 1](#f0005){ref-type="fig"}; [Table S1](#s0085){ref-type="fn"}). All of the 17 research articles were retrospective studies. The publication dates ranged from 1996 to 2012. 1343 patients with osteosarcoma were comprised totally, of whom 617 patients received LSS and 726 received amputation. The results of quality assessment by NOS are shown in [Table 1](#t0005){ref-type="table"}, and the detail information of patients in each articles were listed in [Table 2](#t0010){ref-type="table"}. Among 5 of the studies [@bib20], [@bib22], [@bib25], [@bib30], [@bib31] patients with Enneking Stage-IIA, and Stage-IIB osteosarcoma were both included. For other 5 studies [@bib15], [@bib16], [@bib26], [@bib28], [@bib29], patients with Enneking Stage-IIB osteosarcoma were included. Histologic response to preoperative chemotherapy is reported to be a independent prognostic factor of osteosarcoma [@bib32]. Among the included studies, 7 studies assessed the histologic response to preoperative chemotherapy [@bib16], [@bib17], [@bib18], [@bib21], [@bib23], [@bib25], [@bib28].

3.2. Study heterogeneity and publication bias {#s0050}
---------------------------------------------

The *P*-value for study heterogeneity was 0.26, 0.29, 0.80 for three outcomes including local recurrence, 5-year overall survival rate, and metastatic occurrence. As a result of the true difference in terms of treatment effect, clinical characteristics, etc., the variability (*I*^2^) across all studies was 18%, 16%, and 0% for three outcomes respectively. All the results above indicated that there was no heterogeneity among the included studies ( [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}). Moreover, the funnel plots for all outcome measurements were symmetrical ([Fig. 2](#f0010){ref-type="fig"}A--C). All the spots representing individual studies fell evenly within the top of the inverted funnel, indicating that there was no publication bias.

3.3. Meta-analysis of local recurrence {#s0055}
--------------------------------------

1127 cases from 14 studies were selected for meta-analysis of local recurrence. The overall incidence of local recurrence in LSS and amputation group was 11.88% (57 of 480) and 7.73% (50 of 647), respectively. The results showed that there was no significant differences between LSS and amputation group (OR: 1.03 with 95% CI ranging from 0.65 to 3.30; *Z*=0.14, *P*=0.89) ([Table 3](#t0015){ref-type="table"}; [Fig. 3](#f0015){ref-type="fig"}).

3.4. Meta-analysis of 5-year overall survival {#s0060}
---------------------------------------------

Totally, 1074 cases from 10 studies were analyzed for 5-year overall survival. The 5-year overall survival rate in LSS and amputation group was 58.60% (252 of 430) and 49.84% (321 of 644), respectively. In patients treated with LSS, the 5-year overall survival rate was significantly higner than those treated with amputation (OR: 1.47 with 95% CI ranging from 1.10 to 1.97; *Z*=2.61, *P*\<0.05) ([Table 4](#t0020){ref-type="table"}; [Fig. 4](#f0020){ref-type="fig"}).

3.5. Meta-analysis of metastasis occurrence {#s0065}
-------------------------------------------

125 cases from 4 studies were analyzed for metastatic analysis. The overall incidence of metastasis occurrence in LSS and amputation group was 22.67% (17 of 75) and 44% (22 of 50), respectively. Patients treated with LSS had a significantly lower metastasis occurrence compared those with amputation (OR: 0.24 with 95% CI ranging from 0.10 to 0.60; *Z*=3.05, *P*\<0.05) ([Table 5](#t0025){ref-type="table"}; [Fig. 5](#f0025){ref-type="fig"}).

4. Discussion {#s0070}
=============

With the improved efficacy of chemotherapy, the number of patients with osteosarcoma who received LSS instead of amputation has significantly increased recent years [@bib33], [@bib34], [@bib35], [@bib36], [@bib37]. Moreover, LSS benefits not only malignant primary osteosarcoma patients, but also high-grade, localized osteosarcoma patients. However, there are substantial studies showing that the survival rate and local recurrence between LSS and amputation for osteosarcoma have been conflicting [@bib25], [@bib38]. In this study, it was concluded that patients treated with LSS had a similar local recurrence and a lower metastasis occurrence compared with those treated with amputation, which was identical with that of Yin [@bib14] but with more expansive literature included in our study. In addition, we found that 5-year overall survival rate of patients treated with LSS was higher than those treated with amputation. Therefore, our results provide more comprehensive evidence to support LSS for the treatment of osteosarcoma patients.

In the meta-analysis of local recurrence of LSS vs. amputation for the treatment of osteosarcoma, there was no significant difference in the two surgery methods (OR: 1.03 with 95% CI ranging from 0.65 to 3.30; *Z*=0.14, *P*=0.89) ([Table 3](#t0015){ref-type="table"}; [Fig. 3](#f0015){ref-type="fig"}). In five of 17 articles, the local recurrence rate in patients undergoing LSS was dramatically higher than those receiving amputation [@bib15], [@bib19], [@bib23], [@bib25], [@bib29]. The sample sizes of these five studies were relatively small. Differently from these studies, other included studies revealed similar local recurrence rates between the two surgery methods. Moreover, in a study of Bacci et al. [@bib17] with more than 500 samples investigated, local recurrence rates were found to be similar between LSS and amputation, which offered solid evidence to evaluate the local recurrence of LSS for the treatment of osteosarcoma.

In this meta-analysis, the overall survival at 5 years was slightly better in those treated by LSS than those who had amputation(OR: 1.47 with 95% CI ranging from 1.10 to 1.97; *Z*=2.61, *P*\<0.05)for treating osteosarcoma patients. Among the included studies, only two studies of Xu et al., Hegyi et al. [@bib21], [@bib29] found that the amputation resulted in better 5-year survival. Abudu et al. [@bib15] found that amputation didn't come with a prolonged overall survival, though it provide better eradication of local tumor than LSS. However, in another article which was not included in the meta-analysis [@bib39], it was indicated that LSS did not affect the survival rate. Even through our analysis results were somewhat inconsistent with previous research, we still concluded that LSS had a similar 5-year overall survival rate to that of amputation.

The metastatic occurrence rate for patients treated with LSS was significantly lower than those treated with amputation (OR: 0.24 with 95% CI ranging from 0.10 to 0.60; *Z*=3.05, *P*\<0.05) ([Table 5](#t0025){ref-type="table"}; [Fig. 5](#f0025){ref-type="fig"}), which was identical with the results of Yin et al. [@bib14]. However, only 4 of 17 studies reported the metastasis, including 125 patients. Abudu [@bib15] found that the treatment of LSS or amputation influenced the development of metastases to some degree, 44% in patients with LSS and 69% in patients with amputation; Niu [@bib26] reported that metastasis happened in 25% patients treated with LSS compared with 60% in patients treated with amputation; in the study of Mavrogenis et al. [@bib22], one of 23 patients receiving LSS developed metastasis while 3 of 19 patients receiving amputation did; in another study, one of 13 patients undergoing LSS had metastatic occurrence and 4 of 8 patients undergoing amputation had metastatic occurrence [@bib17]. Our analysis of metastatic occurrence was based on only four articles. There are some important prognostic factors of osteosarcoma, such as radical resectability of the tumor, extent of disease at diagnosis, initial tumor volume, and response to neoadjuvant chemotherapy[@bib40], which makes the comparison of the two surgery methods complicate. Thus, additional high-quality, randomized controlled studies are needed to confirm the conclusions.

5. Conclusions {#s0075}
==============

In conclusion, our meta-analysis highlighted that LSS can be safely used in localized osteosarcoma patients with lower metastatic occurrence and better survival, which won't increase the risk for local recurrence. And our meta-analysis supported the conclusions proposed by Yin et al. and provided more comprehensive evidence to support application of LSS for the treatment of osteosarcoma patients.

6. Limitation {#s0080}
=============

In our study, all the articles were retrospective designed, and most of the included studies had small sample sizes that were subjected to systematic and random bias. The small sample size here was more likely to be the main reason for the failure in detecting heterogeneity in articles if it did exist, as the test power of heterogeneity was low in this situation. Moreover, the number in some studies of events for the outcome measurement was very low. Finally, the details of Enneking Stage and response to preoperative chemotherapy were missing for some studies. Therefore, even our study represented more comprehensive evidence compared with previous studies, the conclusions should be confirmed by high-quality, randomized-controlled, large-sample studies.
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==================================
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###### 

Quality assessment for the 17 included articles based on Newcastle--Ottawa quality assessment scale.

Table 1

                               Selection   Comparability   Exposure                                 
  ---------------------------- ----------- --------------- ---------- ---- ---- ---- ---- ---- ---- -----
  Abudu et al. [@bib12]        \*          --              \*         \*   \*   \*   \*   \*   \*   8\*
  Bacci et al. [@bib13]        \*          --              \*         \*   \*   \*   \*   --   --   6\*
  Bacci et al.^b^[@bib14]      \*          \*              \*         --   --   \*   \*   \*   \*   7\*
  Bramer et al. [@bib15]       \*          \*              \*         \*   --   \*   \*   --   --   6\*
  Ferguson et al. [@bib16]     \*          --              \*         \*   --   \*   \*   --   --   5\*
  Guo et al. [@bib17]          \*          --              \*         \*   --   \*   \*   --   \*   6\*
  Hegyi et al. [@bib18]        \*          \*              \*         --   --   \*   \*   \*   \*   7\*
  Jiang et al. [@bib19]        \*          \*              \*         \*   \*   \*   \*   --   --   8\*
  Kim et al. [@bib20]          \*          --              \*         \*   --   \*   \*   --   --   5\*
  Ma et al. [@bib21]           \*          \*              \*         \*   --   \*   --   \*   --   6\*
  Mavrogenis et al. [@bib22]   \*          --              \*         \*   --   \*   \*   --   \*   6\*
  Niu et al. [@bib23]          \*          --              \*         \*   \*   \*   \*   \*   \*   8\*
  Robert et al. [@bib24]       \*          \*              \*         \*   --   --   \*   \*   --   6\*
  Scully et al. [@bib25]       \*          \*              \*         \*   \*   \*   \*   \*   --   8\*
  Xu et al. [@bib26]           \*          \*              \*         \*   \*   \*   \*   \*   --   8\*
  Zhang et al. [@bib27]        \*          --              \*         \*   \*   \*   \*   --   \*   7\*
  Zhao et al. [@bib28]         \*          \*              \*         \*   \*   \*   \*   --   --   7\*

###### 

Characteristic of the 17 included studies.

  Ref.                       Abudu et al. [@bib12]   Bacci et al. [@bib13]   Bacci et al.^b^[@bib14]   Bramer et al. [@bib15]   Ferguson et al. [@bib16]   Guo et al. [@bib17]    Hegyi et al. [@bib18]   Jiang et al. [@bib19]   Kim et al. [@bib20]
  -------------------------- ----------------------- ----------------------- ------------------------- ------------------------ -------------------------- ---------------------- ----------------------- ----------------------- ---------------------
  Country                    England                 Italy                   Italy                     UK                       Canada                     China                  Hungary                 China                   Korea
  Patient Number             40                      46                      560                       56                       31                         21                     122                     64                      37
  LSS,                       27                      35                      95                        44                       19                         13                     92                      32                      3
  Amputation                 13                      11                      465                       12                       12                         8                      30                      32                      4
  Study period               1975--1994              1983--1999              1983--1995                1983--2003               1989--2006                 1998--2008             1988--2006              2001--2011              --
  Male                       25                      24                      320                       36                       14                         14                     65                      46                      26
  Female                     14                      22                      240                       20                       17                         7                      57                      18                      11
  Median age(range), years   18 (2--46)              11 (3--20)              --                        16 (4--57)               30 (11--8)                 14.5 (9--17)           13.8±3.6a               18.4±6.3 (12--30)       --
  Enneking stage             Stage-IIB               Stage-IIB               --                        --                       --                         Stage-IIA, Stage-IIB   --                      Stage-IIA, Stage-IIB    --
  Follow-up(range), months   55 (8--175)             132 (36--240)           22.6 (3--96)              117 (7--252)             --                         38 (28--62)            --                      8--42                   43 (10--228)
  Poor chemotherapy          --                      12 (26%)                194 (35%)                 43 (78%)                 --                         --                     67 (55%)                --                      23 (62%)
  Local recurrence                                                                                                                                                                                                                
  LSS                        5                       1                       6                         6                        2                          2                      --                      2                       4
  Amputation                 0                       1                       20                        2                        0                          --                     --                      2                       0
  5-year Survival                                                                                                                                                                                                                 
  LSS                        17                      --                      60                        --                       --                         9                      58                      25                      --
  Amputation                 6                       --                      230                       --                       --                         3                      23                      19                      --
  Metastatic occurrence                                                                                                                                                                                                           
  LSS                        12                      --                      --                        --                       --                         1                      --                      --                      --
  Amputation                 9                       --                      --                        --                       --                         4                      --                      --                      --

  -------------------------- -------------------- ---------------------------- --------------------- ------------------------ ------------------------ -------------------- ----------------------- ----------------------
  Ref.                       Ma et al. [@bib21]   Mavrogenis et al. [@bib22]   Niu et al. [@bib23]   Robert et al. [@bib24]   Scully et al. [@bib25]   Xu et al. [@bib26]   Zhang et al. [@bib27]   Zhao et al. [@bib28]
  Country                    China                Italy                        China                 USA                      USA                      China                China                   China
  Patient Number             51                   42                           22                    57                       52                       58                   31                      53
  LSS,                       32                   23                           12                    33                       30                       43                   17                      37
  Amputation                 19                   19                           10                    24                       22                       15                   14                      16
  Study period               1991--1999           1985--2010                   1992--2001            2007--2008               1977--1996               1992--2002           --                      1996--2007
  Male                       35                   23                           15                    20                       28                       30                   26                      --
  Female                     16                   19                           7                     37                       24                       28                   5                       --
  Median Age(range), years   22.3 (10--47)a       26 (7--78)a                  18 (3--36)            33.8 (16.1--52)          23±17.4a                 20.26 (12--55)       17a                     19.5 (5--45)a
  Enneking stage             --                   Stage-IIA, Stage-IIB         Stage-IIB             --                       Stage-IIB                Stage-IIB            Stage-IIA, Stage-IIB    Stage-IIA, Stage-IIB
  Follow-up(range), months   72 (60--144)         60 (8--288)                  54.7 (8--146)         223.2 (39.6--338.4)      54 (6--152.4)            129.6 (72--192)      43.2                    --
  Poor chemotherapy          --                   7 (17%)                      --                    --                       29 (64%)                 --                   --                      --
  Local recurrence                                                                                                                                                                                  
  LSS                        2                    5                            2                     --                       7                        7                    5                       3
  Amputation                 --                   2                            1                     --                       4                        1                    12 (                    1
  5-year Survival                                                                                                                                                                                   
  LSS                        12                   --                           8                     --                       19                       19                   6                       19
  Amputation                 7                    --                           4                     --                       12                       8\)                  1                       
  Metastatic Occurrence                                                                                                                                                                             
  LSS                        --                   1                            3                     --                       --                       --                                           
  Amputation                 --                   3                            6                     --                       --                       --                                           
  -------------------------- -------------------- ---------------------------- --------------------- ------------------------ ------------------------ -------------------- ----------------------- ----------------------

###### 

Statistic summary of forest plot of comparison: local recurrence of LSS vs. amputation for the treatment of osteosarcoma.

Table 3

  Study               LSS   Amputation   Weight (%)   Odds Ratio           
  ------------------- ----- ------------ ------------ ------------ ------- -----------------------
  Abudu et al.        5     27           0            13           1.5     6.60 \[0.34, 128.99\]
  Bacci et al.        1     35           1            11           4.2     0.29 \[0.02, 5.14\]
  Bacci et al.^b^     6     95           20           465          17.9    1.50 \[0.59, 3.84\]
  Bramer et al.       6     44           2            12           7.6     0.78 \[0.14, 4.52\]
  Ferguson et al.     2     19           0            12           1.5     3.57 \[0.16, 81.03\]
  Guo et al.          2     13           5            8            14.8    0.11 \[0.01, 0.87\]
  Jiang et al.        2     32           2            32           5.3     1.00 \[0.13, 7.57\]
  Kim et al.          4     33           0            4            2.1     1.37 \[0.06, 30.04\]
  Mavrogenis et al.   5     23           2            19           4.8     2.36 \[0.40, 13.84\]
  Niu et al.          2     12           1            10           0.0     1.80 \[0.14, 23.37\]
  Scully et al.       7     30           4            22           10.0    1.37 \[0.35, 5.41\]
  Xu et al.           7     43           1            15           3.5     2.72 \[0.31, 24.19\]
  Zhang et al.        5     17           12           18           23.2    0.21 \[0.05, 0.87\]
  Zhao et al.         3     37           1            16           3.6     1.32 \[0.13, 13.79\]
  Total (95%) CI      57    480          50           647          100.0   1.03 \[0.65, 1.64\]

Heterogeneity: *χ*^2^=14.47, df=12 (P=0.26); *I*^2^=18%.

Test for over effect: *Z*=0.14 (*P*=0.89).

###### 

Statistic summary of forest plot of comparison: 5-year overall survival of LSS vs. amputation for the treatment of osteosarcoma.

Table 4

  Study             LSS   Amputation   Weight (%)   Odds Ratio           
  ----------------- ----- ------------ ------------ ------------ ------- ----------------------
  Abudu et al.      17    27           6            13           4.0     1.98 \[0.52, 7.58\]
  Bacci et al.^b^   60    95           230          465          38.5    1.75 \[1.11, 2.76\]
  Guo et al.        9     13           3            8            1.5     3.75 \[0.59, 23.94\]
  Hegyi et al.      58    92           23           30           17.2    0.52 \[0.20, 1.34\]
  Jiang et al.      25    32           19           32           5.6     2.44 \[0.82, 7.31\]
  Ma et al.         12    32           7            19           7.4     1.03 \[0.32, 3.33\]
  Niu et al.        8     12           4            10           1.9     3.00 \[0.52, 17.16\]
  Scully et al.     19    30           12           22           6.8     1.44 \[0.47, 4.41\]
  Xu et al.         19    43           8            15           8.9     0.69 \[0.21, 2.25\]
  Zhang et al.      6     17           1            14           1.0     7.09 \[0.74, 68.24\]
  Zhao et al.       19    37           8            16           7.3     1.06 \[0.33, 3.41\]
  Total (95%) CI    252   430          321          644          100.0   1.47 \[ 1.10, 1.97\]

Heterogeneity: *χ*^2^=11.94, df=10 (P=0.29); I^2^=16%.

Test for overall effect: *Z*=2.61 (*P*=0.009).

###### 

Statistic summary of forest plot of comparison: metastatic occurrence in patients receiving LSS vs. amputation for the treatment of osteosarcoma.

Table 5

  Study               LSS   Amputation   Weight (%)   Odds ratio           
  ------------------- ----- ------------ ------------ ------------ ------- ---------------------
  Abudu et al.        12    27           9            13           34.8    0.36 \[0.09, 1.44\]
  Guo et al.          1     13           4            8            23.6    0.08 \[0.01, 0.98\]
  Mavrogenis et al.   1     23           3            19           16.2    0.24 \[0.02, 2.55\]
  Niu et al.          3     12           6            10           25.3    0.22 \[0.04, 1.37\]
  Total (95%) CI      17    75           22           50           100.0   0.24 \[0.10, 0.60\]

Heterogeneity: *χ*^2^=1.02, df=3 (P=0.80); I^2^=0%.

Test for overall effect: *Z*=3.05 (*P*=0.002).

[^1]: These authors contributed equally to this work, and each is considered as a first author.
